For patients with cancer receiving a bone-modifying agent (bisphosphonate or denosumab) who suffer a fracture requiring stabilization or reconstruction, how do you manage the bone-modifying agent peri-operatively?  

Is there concern for impaired healing? Do you pause therapy and for how long?



Answer from: Medical Oncologist at Community Practice